Chief Business Officer
Edward “Tad” Stewart has more than 20 years of strategic biopharmaceutical business development experience, including over fifteen years at Merrimack Pharmaceuticals. During his time at Merrimack, Tad served in various roles as part of the executive leadership team, including leading the company’s business development efforts and heading the company’s Commercial Business Unit. Tad’s experience at Merrimack spanned its growth from a pre-clinical organization to a clinical development company and, ultimately, to a commercial enterprise, including the successful launch of a marketed oncology product (ONIVYDE®) and the execution of several strategic transactions that supported the long-term growth of the company. Most recently he served as President and CEO of Commense, Inc., a company focused on developing pediatric immunomodulators based on manipulating the human microbiome. Prior to Commense, Tad served as Chief Business Officer for Crescendo Biologics, a novel antibody platform company. Prior to Merrimack, Tad worked as a consultant with clients across the biotech, pharmaceutical and medical device industries.
Tad holds an M.B.A. from the Johnson School at Cornell University and a B.S. in Biology from Bates College.